70,000 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Purchased by Capital Advisors Wealth Management LLC

Capital Advisors Wealth Management LLC purchased a new stake in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 70,000 shares of the company's stock, valued at approximately $891,000. Capital Advisors Wealth Management LLC owned approximately 0.21% of Delcath Systems as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DCTH. Quarry LP bought a new position in shares of Delcath Systems in the fourth quarter valued at about $34,000. Quantbot Technologies LP acquired a new stake in Delcath Systems in the 4th quarter valued at about $66,000. Inlight Wealth Management LLC bought a new position in shares of Delcath Systems in the first quarter worth about $85,000. Graham Capital Management L.P. acquired a new position in shares of Delcath Systems during the fourth quarter worth approximately $123,000. Finally, NBC Securities Inc. grew its stake in shares of Delcath Systems by 99,900.0% during the first quarter. NBC Securities Inc. now owns 10,000 shares of the company's stock valued at $127,000 after purchasing an additional 9,990 shares during the last quarter. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Price Performance

DCTH opened at $13.57 on Friday. The firm has a 50 day simple moving average of $14.65 and a 200 day simple moving average of $13.78. Delcath Systems, Inc. has a fifty-two week low of $7.17 and a fifty-two week high of $18.23. The company has a market cap of $472.64 million, a price-to-earnings ratio of -27.14 and a beta of 0.95.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative net margin of 26.38% and a negative return on equity of 29.44%. The business had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. As a group, analysts expect that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on DCTH shares. HC Wainwright restated a "buy" rating and issued a $29.00 price objective (up previously from $24.00) on shares of Delcath Systems in a research report on Friday, May 23rd. Stephens reissued an "overweight" rating and issued a $25.00 target price on shares of Delcath Systems in a research note on Monday, June 23rd. Finally, Wall Street Zen downgraded Delcath Systems from a "strong-buy" rating to a "buy" rating in a research report on Sunday, June 1st. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $24.00.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Want to see what other hedge funds are holding DCTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Delcath Systems, Inc. (NASDAQ:DCTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.